CD274 and breast cancer: Knockout of PD-L1 by Cas9-g82/165 + HDR was also confirmed in a human breast cancer cell line MDA MB 231) (Fig. 3D, E, Supplemental Fig. 4), suggesting Cas9-g82/165 + HDR was capable of targeting human PD-L1.